Dr. Weinberg recaps key ASCO Annual Meeting research, including MATTERHORN, ATOMIC CHALLENGE, BREAKWATER, and DYNAMIC-III.
Gastric
Advertisement
The panel concludes with a discussion on treatment strategies for metastatic esophageal squamous cell carcinoma.
The panel shifts focus to the 1L treatment of metastatic gastroesophageal cancers, exploring biomarker testing strategies.
The panel delves into the implications of recent data on IO in the perioperative, adjuvant treatment of upper GI cancers.
The panel takes a deep dive into the evolving role of IO in resectable GE cancer, with a focus on the results of MATTERHORN.
The panel launches into a discussion of practice-changing data, focusing on MATTERHORN and its impact on disease management.
Dr. Janjigian shares why MATTERHORN was picked for the plenary and how its findings build on past studies in G/GEJ cancer.
Dr. Pietrantonio discusses how the benefits of T-DXd can potentially reshape the current treatment algorithm.
In the first-line HER2+ G/GEJ cancer, combinations of DV, toripalimab, and chemo produce high ORRs and promising early PFS.
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
We recently spoke with expert clinicians about the rapidly changing treatment landscape in upper gastrointestinal cancers.
Roundtables
Video Insights
Advertisement
Section Editor
Samuel Cytryn, MDGastrointestinal Medical Oncologist | Memorial Sloan Kettering Cancer Center
Advertisement
Latest GI Oncology News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.